Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX1 | P51575 | 3/20 | 1.00 |
| ▸ | P2RX3 | P56373 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | ENPP1 | P22413 | 6/20 | 0.86 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.86 |
| ▸ | NT5E | P21589 | 1/20 | 0.86 |
| ▸ | P2RY1 | P47900 | 7/20 | 0.86 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.86 |
| ▸ | SRC | P12931 | 2/20 | 0.86 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.86 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.86 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.86 |
| ▸ | P2RY11 | Q96G91 | 2/20 | 0.84 |
| ▸ | TRPM2 | O94759 | 2/20 | 0.80 |
| ▸ | MACROD2 | A1Z1Q3 | 1/20 | 0.80 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.80 |
| ▸ | MACROD1 | Q9BQ69 | 1/20 | 0.80 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.76 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.76 |
| ▸ | LDHA | P00338 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-8008274-B2 | P1-(2′-deoxycytidine 5′-)P4-(uridine 5′-)tetraphosphate, tetra-(alkali metal) salt, for treating sinusitis | INSPIRE PHARMACEUTICALS, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| WO-2011077435-A1 | COMPOSITIONS AND METHODS FOR REDUCING INTRAOCULAR PRESSURE | BAR-ILAN UNIVERSITY (IL) | 2011-06-30 | — | — | WO | disclosed |
| US-20090306010-A1 | P1-(2'-DEOXYCYTIDINE 5'-)P4-(URIDINE 5'-)TETRAPHOSPHATE, TETRA-(ALKALI METAL) SALT, FOR TREATING DISORDERS | MERCK SHARP & DOHME CORP. | 2009-12-10 | — | — | US | disclosed |
| US-7531525-B2 | P1-(2′-deoxycytidine 5′-)P4-(uridine 5′-)tetraphosphate, tetra-(alkali metal) salt, for treating cystic fibrosis | INSPIRE PHARMACEUTICALS, INC. (US) | 2009-05-12 | — | — | US | disclosed |
| US-20070197454-A1 | P1-(2'-DEOXYCYTIDINE 5'-)P4-(URIDINE 5'-)TETRAPHOSPHATE, TETRA-(ALKALI METAL) SALT, FOR TREATING DISORDERS | MERCK SHARP & DOHME LLC | 2007-08-23 | — | — | US | disclosed |
| US-7223744-B2 | Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof | INSPIRE PHARMACEUTICALS, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20050085439-A1 | Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof | MERCK SHARP & DOHME LLC | 2005-04-21 | — | — | US | disclosed |
| US-6818629-B2 | ADMINISTRATION OF A PHARMACEUTICAL FORMULATION COMPRISING A HYDROLYSIS-RESISTANT P2Y RECEPTOR AGONIST TO STIMULATE THE REMOVAL OF PATHOLOGICAL EXTRANEOUS FLUID FROM THE SUBRETINAL AND RETINAL SPACES; DINUCLEOSIDE POLYPHOSPHATE COMPOUND | INSPIRE PHARMACEUTICALS, INC. | 2004-11-16 | — | — | US | disclosed |
| US-20030186917-A1 | Method of treating edematous retinal disorders | MERCK SHARP & DOHME CORP. | 2003-10-02 | — | — | US | disclosed |
| EP-0831855-A1 | NUCLEOTIDE ANALOGUES FOR TOPICAL TREATMENT OF PROLIFERATIVE DISEASE OF THE SKIN | HOSTETLER, Karl Y. (US) | 1998-04-01 | — | — | EP | disclosed |
| US-5654286-A | Nucleotides for topical treatment of psoriasis, and methods for using same | HOSTETLER KARL Y (US) | 1997-08-05 | — | — | US | disclosed |
| WO-1996040166-A1 | NUCLEOTIDE ANALOGUES FOR TOPICAL TREATMENT OF PROLIFERATIVE DISEASE OF THE SKIN | HOSTETLER KARL Y (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085439-A1 | Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof | P2RY1, P2RY11, P2RY6 | P2RX1 13/4885P2RX3 11/4885ALDH1A1 3022/4885 |
| US-20030186917-A1 | Method of treating edematous retinal disorders | P2RY1, P2RY11, P2RY2 | P2RX1 13/4885P2RX3 9/4885ALDH1A1 2918/4885 |
| US-20070197454-A1 | P1-(2'-DEOXYCYTIDINE 5'-)P4-(URIDINE 5'-)TETRAPHOSPHATE, TETRA-(ALKALI METAL) SALT, FOR TREATING DISORDERS | P2RY1, P2RY4, P2RY6 | P2RX1 6/4885P2RX3 10/4885ALDH1A1 1656/4885 |
| US-20090306010-A1 | P1-(2'-DEOXYCYTIDINE 5'-)P4-(URIDINE 5'-)TETRAPHOSPHATE, TETRA-(ALKALI METAL) SALT, FOR TREATING DISORDERS | P2RY1, P2RY4, P2RY2 | P2RX1 8/4885P2RX3 9/4885ALDH1A1 1771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.